<?xml version="1.0" ?>
<!DOCTYPE PubmedArticleSet PUBLIC "-//NLM//DTD PubMedArticle, 1st January 2023//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/out/pubmed_230101.dtd">
<PubmedArticleSet>
<PubmedArticle><MedlineCitation Status="MEDLINE" Owner="NLM"><PMID Version="1">31611269</PMID><DateCompleted><Year>2020</Year><Month>10</Month><Day>01</Day></DateCompleted><DateRevised><Year>2020</Year><Month>10</Month><Day>01</Day></DateRevised><Article PubModel="Electronic-Print"><Journal><ISSN IssnType="Electronic">2332-7812</ISSN><JournalIssue CitedMedium="Internet"><Volume>6</Volume><Issue>6</Issue><PubDate><Year>2019</Year><Month>Nov</Month></PubDate></JournalIssue><Title>Neurology(R) neuroimmunology &amp; neuroinflammation</Title><ISOAbbreviation>Neurol Neuroimmunol Neuroinflamm</ISOAbbreviation></Journal><ArticleTitle>IL6 receptor<sup>358</sup>Ala variant and trans-signaling are disease modifiers in amyotrophic lateral sclerosis.</ArticleTitle><Pagination><StartPage>e631</StartPage><MedlinePgn>e631</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1212/NXI.0000000000000631</ELocationID><Abstract><AbstractText Label="OBJECTIVE">To test the hypothesis that patients with amyotrophic lateral sclerosis (ALS) inheriting the common interleukin 6 receptor (IL6R) coding variant (Asp<sup>358</sup>Ala, rs2228145, C allele) have associated increases in interleukin 6 (IL6) and IL6R levels in serum and CSF and faster disease progression than noncarriers.</AbstractText><AbstractText Label="METHODS">An observational, case-control study of paired serum and CSF of 47 patients with ALS, 46 healthy, and 23 neurologic disease controls from the Northeastern ALS Consortium Biofluid Repository (cohort 1) was performed to determine serum levels of IL6, sIL6R, and soluble glycoprotein 130 and compared across groups and IL6R genotype. Clinical data regarding disease progression from a separate cohort of 35 patients with ALS from the Wake Forest ALS Center (cohort 2) were used to determine change in ALSFRS-R scores by genotype.</AbstractText><AbstractText Label="RESULTS">Patients with ALS had increased CSF IL6 levels compared with healthy (<i>p</i> &lt; 0.001) and neurologic (<i>p</i> = 0.021) controls. Patients with ALS also had increased serum IL6 compared with healthy (<i>p</i> = 0.040) but not neurologic controls. Additive allelic increases in serum IL6R were observed in all groups (average increase of 52% with the presence of the IL6R C allele; <i>p</i> &lt; 0.001). However, only subjects with ALS had significantly increased CSF sIL6R levels compared with controls (<i>p</i> &lt; 0.001). When compared across genotypes, only patients with ALS inheriting the IL6R C allele exhibit increased CSF IL6. ALSFRS-R scores decreased more in patients with ALS with the IL6R C allele than in those without (<i>p</i> = 0.019).</AbstractText><AbstractText Label="CONCLUSIONS">Theses results suggest that for individuals inheriting the IL6R C allele, the cytokine exerts a disease- and location-specific role in ALS. Follow-up, prospective studies are necessary, as this subgroup of patients may be identified as ideally responsive to IL6 receptor-blocking therapies.</AbstractText><CopyrightInformation>Copyright &#xa9; 2019 The Author(s). Published by Wolters Kluwer Health, Inc. on behalf of the American Academy of Neurology.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Wosiski-Kuhn</LastName><ForeName>Marlena</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>From the Department of Neurobiology and Anatomy (M.W.-K., M.R., J.S., P.A., M.M., C.M.); Department of Neurology (J.C., M. Cartwright); and Department of Biochemistry (G.A.H.), Wake Forest School of Medicine; Division of Public Health (C.L.), Department of Biostatistical Sciences, Wake Forest School of Medicine; Departments of Neurology and Neurobiology (R.B.), Barrow Neurological Institute &amp; St. Joseph's Hospital and Medical Center; Department of Neurology (M. Cudkowicz), Neurological Clinical Research Institute, Massachusetts General Hospital, Harvard Medical School; and Current Address Department of Pediatrics (M.M.), Nationwide Children's Hospital, Columbus OH.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Robinson</LastName><ForeName>Mac</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>From the Department of Neurobiology and Anatomy (M.W.-K., M.R., J.S., P.A., M.M., C.M.); Department of Neurology (J.C., M. Cartwright); and Department of Biochemistry (G.A.H.), Wake Forest School of Medicine; Division of Public Health (C.L.), Department of Biostatistical Sciences, Wake Forest School of Medicine; Departments of Neurology and Neurobiology (R.B.), Barrow Neurological Institute &amp; St. Joseph's Hospital and Medical Center; Department of Neurology (M. Cudkowicz), Neurological Clinical Research Institute, Massachusetts General Hospital, Harvard Medical School; and Current Address Department of Pediatrics (M.M.), Nationwide Children's Hospital, Columbus OH.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Strupe</LastName><ForeName>Jane</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>From the Department of Neurobiology and Anatomy (M.W.-K., M.R., J.S., P.A., M.M., C.M.); Department of Neurology (J.C., M. Cartwright); and Department of Biochemistry (G.A.H.), Wake Forest School of Medicine; Division of Public Health (C.L.), Department of Biostatistical Sciences, Wake Forest School of Medicine; Departments of Neurology and Neurobiology (R.B.), Barrow Neurological Institute &amp; St. Joseph's Hospital and Medical Center; Department of Neurology (M. Cudkowicz), Neurological Clinical Research Institute, Massachusetts General Hospital, Harvard Medical School; and Current Address Department of Pediatrics (M.M.), Nationwide Children's Hospital, Columbus OH.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Arounleut</LastName><ForeName>Phonepasong</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>From the Department of Neurobiology and Anatomy (M.W.-K., M.R., J.S., P.A., M.M., C.M.); Department of Neurology (J.C., M. Cartwright); and Department of Biochemistry (G.A.H.), Wake Forest School of Medicine; Division of Public Health (C.L.), Department of Biostatistical Sciences, Wake Forest School of Medicine; Departments of Neurology and Neurobiology (R.B.), Barrow Neurological Institute &amp; St. Joseph's Hospital and Medical Center; Department of Neurology (M. Cudkowicz), Neurological Clinical Research Institute, Massachusetts General Hospital, Harvard Medical School; and Current Address Department of Pediatrics (M.M.), Nationwide Children's Hospital, Columbus OH.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Martin</LastName><ForeName>Matthew</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>From the Department of Neurobiology and Anatomy (M.W.-K., M.R., J.S., P.A., M.M., C.M.); Department of Neurology (J.C., M. Cartwright); and Department of Biochemistry (G.A.H.), Wake Forest School of Medicine; Division of Public Health (C.L.), Department of Biostatistical Sciences, Wake Forest School of Medicine; Departments of Neurology and Neurobiology (R.B.), Barrow Neurological Institute &amp; St. Joseph's Hospital and Medical Center; Department of Neurology (M. Cudkowicz), Neurological Clinical Research Institute, Massachusetts General Hospital, Harvard Medical School; and Current Address Department of Pediatrics (M.M.), Nationwide Children's Hospital, Columbus OH.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Caress</LastName><ForeName>James</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>From the Department of Neurobiology and Anatomy (M.W.-K., M.R., J.S., P.A., M.M., C.M.); Department of Neurology (J.C., M. Cartwright); and Department of Biochemistry (G.A.H.), Wake Forest School of Medicine; Division of Public Health (C.L.), Department of Biostatistical Sciences, Wake Forest School of Medicine; Departments of Neurology and Neurobiology (R.B.), Barrow Neurological Institute &amp; St. Joseph's Hospital and Medical Center; Department of Neurology (M. Cudkowicz), Neurological Clinical Research Institute, Massachusetts General Hospital, Harvard Medical School; and Current Address Department of Pediatrics (M.M.), Nationwide Children's Hospital, Columbus OH.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cartwright</LastName><ForeName>Michael</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>From the Department of Neurobiology and Anatomy (M.W.-K., M.R., J.S., P.A., M.M., C.M.); Department of Neurology (J.C., M. Cartwright); and Department of Biochemistry (G.A.H.), Wake Forest School of Medicine; Division of Public Health (C.L.), Department of Biostatistical Sciences, Wake Forest School of Medicine; Departments of Neurology and Neurobiology (R.B.), Barrow Neurological Institute &amp; St. Joseph's Hospital and Medical Center; Department of Neurology (M. Cudkowicz), Neurological Clinical Research Institute, Massachusetts General Hospital, Harvard Medical School; and Current Address Department of Pediatrics (M.M.), Nationwide Children's Hospital, Columbus OH.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Bowser</LastName><ForeName>Robert</ForeName><Initials>R</Initials><AffiliationInfo><Affiliation>From the Department of Neurobiology and Anatomy (M.W.-K., M.R., J.S., P.A., M.M., C.M.); Department of Neurology (J.C., M. Cartwright); and Department of Biochemistry (G.A.H.), Wake Forest School of Medicine; Division of Public Health (C.L.), Department of Biostatistical Sciences, Wake Forest School of Medicine; Departments of Neurology and Neurobiology (R.B.), Barrow Neurological Institute &amp; St. Joseph's Hospital and Medical Center; Department of Neurology (M. Cudkowicz), Neurological Clinical Research Institute, Massachusetts General Hospital, Harvard Medical School; and Current Address Department of Pediatrics (M.M.), Nationwide Children's Hospital, Columbus OH.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Cudkowicz</LastName><ForeName>Merit</ForeName><Initials>M</Initials><AffiliationInfo><Affiliation>From the Department of Neurobiology and Anatomy (M.W.-K., M.R., J.S., P.A., M.M., C.M.); Department of Neurology (J.C., M. Cartwright); and Department of Biochemistry (G.A.H.), Wake Forest School of Medicine; Division of Public Health (C.L.), Department of Biostatistical Sciences, Wake Forest School of Medicine; Departments of Neurology and Neurobiology (R.B.), Barrow Neurological Institute &amp; St. Joseph's Hospital and Medical Center; Department of Neurology (M. Cudkowicz), Neurological Clinical Research Institute, Massachusetts General Hospital, Harvard Medical School; and Current Address Department of Pediatrics (M.M.), Nationwide Children's Hospital, Columbus OH.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Langefeld</LastName><ForeName>Carl</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>From the Department of Neurobiology and Anatomy (M.W.-K., M.R., J.S., P.A., M.M., C.M.); Department of Neurology (J.C., M. Cartwright); and Department of Biochemistry (G.A.H.), Wake Forest School of Medicine; Division of Public Health (C.L.), Department of Biostatistical Sciences, Wake Forest School of Medicine; Departments of Neurology and Neurobiology (R.B.), Barrow Neurological Institute &amp; St. Joseph's Hospital and Medical Center; Department of Neurology (M. Cudkowicz), Neurological Clinical Research Institute, Massachusetts General Hospital, Harvard Medical School; and Current Address Department of Pediatrics (M.M.), Nationwide Children's Hospital, Columbus OH.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hawkins</LastName><ForeName>Gregory A</ForeName><Initials>GA</Initials><AffiliationInfo><Affiliation>From the Department of Neurobiology and Anatomy (M.W.-K., M.R., J.S., P.A., M.M., C.M.); Department of Neurology (J.C., M. Cartwright); and Department of Biochemistry (G.A.H.), Wake Forest School of Medicine; Division of Public Health (C.L.), Department of Biostatistical Sciences, Wake Forest School of Medicine; Departments of Neurology and Neurobiology (R.B.), Barrow Neurological Institute &amp; St. Joseph's Hospital and Medical Center; Department of Neurology (M. Cudkowicz), Neurological Clinical Research Institute, Massachusetts General Hospital, Harvard Medical School; and Current Address Department of Pediatrics (M.M.), Nationwide Children's Hospital, Columbus OH.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Milligan</LastName><ForeName>Carol</ForeName><Initials>C</Initials><AffiliationInfo><Affiliation>From the Department of Neurobiology and Anatomy (M.W.-K., M.R., J.S., P.A., M.M., C.M.); Department of Neurology (J.C., M. Cartwright); and Department of Biochemistry (G.A.H.), Wake Forest School of Medicine; Division of Public Health (C.L.), Department of Biostatistical Sciences, Wake Forest School of Medicine; Departments of Neurology and Neurobiology (R.B.), Barrow Neurological Institute &amp; St. Joseph's Hospital and Medical Center; Department of Neurology (M. Cudkowicz), Neurological Clinical Research Institute, Massachusetts General Hospital, Harvard Medical School; and Current Address Department of Pediatrics (M.M.), Nationwide Children's Hospital, Columbus OH. milligan@wakehealth.edu.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><GrantList CompleteYN="Y"><Grant><GrantID>UL1 TR001420</GrantID><Acronym>TR</Acronym><Agency>NCATS NIH HHS</Agency><Country>United States</Country></Grant></GrantList><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType><PublicationType UI="D013485">Research Support, Non-U.S. Gov't</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2019</Year><Month>10</Month><Day>14</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Neurol Neuroimmunol Neuroinflamm</MedlineTA><NlmUniqueID>101636388</NlmUniqueID><ISSNLinking>2332-7812</ISSNLinking></MedlineJournalInfo><ChemicalList><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C508600">IL6 protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="C508603">IL6R protein, human</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D015850">Interleukin-6</NameOfSubstance></Chemical><Chemical><RegistryNumber>0</RegistryNumber><NameOfSubstance UI="D019947">Receptors, Interleukin-6</NameOfSubstance></Chemical></ChemicalList><CitationSubset>IM</CitationSubset><CommentsCorrectionsList><CommentsCorrections RefType="ErratumIn"><RefSource>Neurol Neuroimmunol Neuroinflamm. 2019 Dec 5;7(1):</RefSource><PMID Version="1">31806685</PMID></CommentsCorrections></CommentsCorrectionsList><MeshHeadingList><MeshHeading><DescriptorName UI="D000328" MajorTopicYN="N">Adult</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000368" MajorTopicYN="N">Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D000690" MajorTopicYN="N">Amyotrophic Lateral Sclerosis</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName><QualifierName UI="Q000503" MajorTopicYN="Y">physiopathology</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D016022" MajorTopicYN="N">Case-Control Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015331" MajorTopicYN="N">Cohort Studies</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D018450" MajorTopicYN="Y">Disease Progression</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D005260" MajorTopicYN="N">Female</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D006801" MajorTopicYN="N">Humans</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D015850" MajorTopicYN="N">Interleukin-6</DescriptorName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading><MeshHeading><DescriptorName UI="D008297" MajorTopicYN="N">Male</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D008875" MajorTopicYN="N">Middle Aged</DescriptorName></MeshHeading><MeshHeading><DescriptorName UI="D019947" MajorTopicYN="N">Receptors, Interleukin-6</DescriptorName><QualifierName UI="Q000235" MajorTopicYN="Y">genetics</QualifierName><QualifierName UI="Q000378" MajorTopicYN="Y">metabolism</QualifierName></MeshHeading></MeshHeadingList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2019</Year><Month>4</Month><Day>26</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2019</Year><Month>8</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2019</Year><Month>10</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2019</Year><Month>10</Month><Day>16</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2020</Year><Month>10</Month><Day>2</Day><Hour>6</Hour><Minute>0</Minute></PubMedPubDate></History><PublicationStatus>epublish</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">31611269</ArticleId><ArticleId IdType="pmc">PMC6865852</ArticleId><ArticleId IdType="doi">10.1212/NXI.0000000000000631</ArticleId><ArticleId IdType="pii">6/6/e631</ArticleId></ArticleIdList><ReferenceList><Reference><Citation>Lyon MS, Wosiski-Kuhn M, Gillespie R, Caress J, Milligan C. Inflammation, immunity, and amyotrophic lateral sclerosis: I. Etiology and pathology. Muscle Nerve 2019;59:10&#x2013;22.</Citation><ArticleIdList><ArticleId IdType="pubmed">29979464</ArticleId></ArticleIdList></Reference><Reference><Citation>Wosiski-Kuhn M, Lyon MS, Caress J, Milligan C. Inflammation, immunity, and amyotrophic lateral sclerosis: II. Immune-modulating therapies. Muscle Nerve 2019;59:23&#x2013;33.</Citation><ArticleIdList><ArticleId IdType="pubmed">29979478</ArticleId></ArticleIdList></Reference><Reference><Citation>Moreau C, Devos D, Brunaud-Danel V, et al. . Elevated IL-6 and TNF-alpha levels in patients with ALS: inflammation or hypoxia? Neurology 2005;65:1958&#x2013;1960.</Citation><ArticleIdList><ArticleId IdType="pubmed">16380619</ArticleId></ArticleIdList></Reference><Reference><Citation>Rentzos M, Rombos A, Nikolaou C, et al. . Interleukin-17 and interleukin-23 are elevated in serum and cerebrospinal fluid of patients with ALS: a reflection of Th17 cells activation? Acta Neurol Scand 2010;122:425&#x2013;429.</Citation><ArticleIdList><ArticleId IdType="pubmed">20219021</ArticleId></ArticleIdList></Reference><Reference><Citation>Mizwicki MT, Fiala M, Magpantay L, et al. . Tocilizumab attenuates inflammation in ALS patients through inhibition of IL6 receptor signaling. Am J Neurodegen Dis 2012;1:305&#x2013;315.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3560466</ArticleId><ArticleId IdType="pubmed">23383400</ArticleId></ArticleIdList></Reference><Reference><Citation>Sekizawa T, Openshaw H, Ohbo K, Sugamura K, Itoyama Y, Niland JC. Cerebrospinal fluid interleukin 6 in amyotrophic lateral sclerosis: immunological parameter and comparison with inflammatory and non-inflammatory central nervous system diseases. J Neurol Sci 1998;154:194&#x2013;199.</Citation><ArticleIdList><ArticleId IdType="pubmed">9562310</ArticleId></ArticleIdList></Reference><Reference><Citation>Zigmond RE. gp130 cytokines are positive signals triggering changes in gene expression and axon outgrowth in peripheral neurons following injury. Front Mol Neurosci 2011;4:62.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3262188</ArticleId><ArticleId IdType="pubmed">22319466</ArticleId></ArticleIdList></Reference><Reference><Citation>Schaper F, Rose-John S. Interleukin-6: biology, signaling and strategies of blockade. Cytokine Growth Factor Rev 2015;26:475&#x2013;487.</Citation><ArticleIdList><ArticleId IdType="pubmed">26189695</ArticleId></ArticleIdList></Reference><Reference><Citation>Campbell IL, Erta M, Lim ML, et al. . Trans-signaling is a dominant mechanism for the pathogenic actions of interleukin-6 in the brain. J Neurosci 2014;34:2503&#x2013;2513.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC6802757</ArticleId><ArticleId IdType="pubmed">24523541</ArticleId></ArticleIdList></Reference><Reference><Citation>Garbers C, Monhasery N, Aparicio-Siegmund S, et al. . The interleukin-6 receptor Asp358AL single nucleotide polymorphism rs2228145 confers increased proteolytic conversion rates by ADAM proteases. Biochemica Biophys Acta 2014;1842:1485&#x2013;1494.</Citation><ArticleIdList><ArticleId IdType="pubmed">24878322</ArticleId></ArticleIdList></Reference><Reference><Citation>van Dongen J, Jansen R, Smit D, et al. . The contribution of the functional IL6R polymorphism rs2228145, eQTLs and other genome-wide SNPs to the heritability of plasma sIL-6R levels. Behav Genet 2014;44:368&#x2013;382.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4283105</ArticleId><ArticleId IdType="pubmed">24791950</ArticleId></ArticleIdList></Reference><Reference><Citation>Bagli M, Papassoritopoulos A, Hampel H, et al. . Polymorphisms of the gene encoding the inflammatory cytokine interleukin-6 determine the magnitude of the increase in soluble interleukin-6 receptor levels in Alzheimer's disease. Eur Arch Psychiatry Clin Neurosci 2003;253:44&#x2013;48.</Citation><ArticleIdList><ArticleId IdType="pubmed">12664314</ArticleId></ArticleIdList></Reference><Reference><Citation>Hawkins GA, Robinson MB, Hastie AT, et al. . The IL6R variation Asp(358)Ala is a potential modifier of lung function in subjects with asthma. J Allergy Clin Immunol 2012;130:510&#x2013;515.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3409329</ArticleId><ArticleId IdType="pubmed">22554704</ArticleId></ArticleIdList></Reference><Reference><Citation>Peters MS, McGrath KW, Hawkins GA, et al. . Plasma interleukin-6 concentrations, metabolic, dysfunction, and asthma severity: a cross-sectional analysis of two cohorts. Lancet Respir Med 2016;4:574&#x2013;584.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5007068</ArticleId><ArticleId IdType="pubmed">27283230</ArticleId></ArticleIdList></Reference><Reference><Citation>Mitsuyama K, Toyonaga A, Sasaki E, et al. . Soluble interleukin-6 receptors in inflammatory bowel disease: relation to circulating interleukin-6. Gut 1995;36:45&#x2013;49.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1382351</ArticleId><ArticleId IdType="pubmed">7890234</ArticleId></ArticleIdList></Reference><Reference><Citation>Stephens OW, Zhang Q, Pingping Q, et al. . An intermediate-risk multiple myeloma subgroup is defined by sIL-6r: levels synergistically increase with incidence of SNP rs2228145 and 1q21 amplification. Blood 2016;119:503&#x2013;511.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3257015</ArticleId><ArticleId IdType="pubmed">22072558</ArticleId></ArticleIdList></Reference><Reference><Citation>Sasayama D, Wakabayashi C, Hori H, et al. . Association of plasma IL-6 and soluble IL-6 receptor levels with the Asp358AL polymorphism of the IL-6 receptor gene in schizophrenic patients. J Psychiatr Res 2011;45:1439&#x2013;1444.</Citation><ArticleIdList><ArticleId IdType="pubmed">21700295</ArticleId></ArticleIdList></Reference><Reference><Citation>Ludolph A, Drory V, Hardiman O, et al. . A revision of the El Escodial criteria. Amyotroph Lateral Scler Frontotemporal Degener 2015;16:291&#x2013;292.</Citation><ArticleIdList><ArticleId IdType="pubmed">26121170</ArticleId></ArticleIdList></Reference><Reference><Citation>Chi&#xf2; A, Logroscino G, Hardiman O, et al. . Prognostic factors in ALS: a critical review. Amyotroph Lateral Scler 1009;10:310&#x2013;323.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3515205</ArticleId><ArticleId IdType="pubmed">19922118</ArticleId></ArticleIdList></Reference><Reference><Citation>Labra J, Menon P, Byth K, Morrison S, Vucic S. Rate of disease progression: a prognostic biomarker in ALS. J Neurol Neurosurg Psychiatry 2016;87;628&#x2013;632.</Citation><ArticleIdList><ArticleId IdType="pubmed">26152368</ArticleId></ArticleIdList></Reference><Reference><Citation>Thakore NJ, Lapin BR, Pioro EP. Trajectories of impairment in amyotrophic lateral sclerosis: insights from the pooled resource open-access ALS clinical trials cohort. Muscle Nerve 2018;57:937&#x2013;945.</Citation><ArticleIdList><ArticleId IdType="pubmed">29244213</ArticleId></ArticleIdList></Reference><Reference><Citation>Cullen T, Thomas AW, Webb R, Hughes MG. The relationship between interleukin-6 in saliva, venous and capillary plasma, at rest and in response to exercise. Cytokine 2015;71:397&#x2013;400.</Citation><ArticleIdList><ArticleId IdType="pubmed">25464926</ArticleId></ArticleIdList></Reference><Reference><Citation>Park HS, Park JY, Yu R. Relationship of obesity and visceral adiposity with serum concentrations of CRP, TNF-&#x3b1; and IL-6. Diabetes Res Clin Pract 2005;69:29&#x2013;35.</Citation><ArticleIdList><ArticleId IdType="pubmed">15955385</ArticleId></ArticleIdList></Reference><Reference><Citation>Ishihara K, Hirano T. IL-6 in autoimmune disease and chronic inflammatory proliferative disease. Cytokine Growth Factor Rev 2002;13:357&#x2013;368.</Citation><ArticleIdList><ArticleId IdType="pubmed">12220549</ArticleId></ArticleIdList></Reference><Reference><Citation>Kastelein T, Duffield R, Marino F. Human in situ cytokine and leukocyte responses to acute smoking. J Immunotoxicol 2017;14:109&#x2013;115.</Citation><ArticleIdList><ArticleId IdType="pubmed">28549401</ArticleId></ArticleIdList></Reference><Reference><Citation>Lee CW, Chen HJ, Liang JA, Kao CH. Risk of sepsis in patients with amyotrophic lateral sclerosis: a population-based retrospective cohort study in Taiwan. BMJ Open 2017;7:e013761.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5253540</ArticleId><ArticleId IdType="pubmed">28093437</ArticleId></ArticleIdList></Reference><Reference><Citation>Lechtzin N, Wiener CM, Clawson L, Chaudhry V, Diette GB. Hospitalization in amyotrophic lateral sclerosis: causes, costs, and outcomes. Neurology 2001;56:753&#x2013;757.</Citation><ArticleIdList><ArticleId IdType="pubmed">11274310</ArticleId></ArticleIdList></Reference><Reference><Citation>Sch&#xf6;bitz B, Pezeshki G, Pohl T, et al. . Soluble interleukin-6 receptor augments central effects of IL-6 in vivo. FASEB J 1995;9:659&#x2013;664.</Citation><ArticleIdList><ArticleId IdType="pubmed">7768358</ArticleId></ArticleIdList></Reference><Reference><Citation>Munoz-Canoves P, Scheele C, Pedersen BK, Serrano AL. Interleukin-6 myokine signaling in skeletal muscle: a double edged sword? FEBS J 2013;280:4131&#x2013;4148.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC4163639</ArticleId><ArticleId IdType="pubmed">23663276</ArticleId></ArticleIdList></Reference><Reference><Citation>Gadient RA, Otten UH. Interleukin-6 (IL-6)&#x2014;a molecule with both beneficial and destructive potentials. Prog Neurobiol 1997;52:379&#x2013;390.</Citation><ArticleIdList><ArticleId IdType="pubmed">9304698</ArticleId></ArticleIdList></Reference><Reference><Citation>Glynn P, Coakley R, Kilgallen I, Murphy N, O'Neill S. Circulating interleukin 6 and interleukin 10 in community acquired pneumonia. Thorax 1999;54:51&#x2013;55.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC1745351</ArticleId><ArticleId IdType="pubmed">10343632</ArticleId></ArticleIdList></Reference><Reference><Citation>Hedlund J. Community-acquired pneumonia requiring hospitalisation. Factors of importance for the short-and long term prognosis. Scand J Infect Dis Suppl 1995;97:1&#x2013;60.</Citation><ArticleIdList><ArticleId IdType="pubmed">8584866</ArticleId></ArticleIdList></Reference><Reference><Citation>Banks WA, Kastin AJ, Gutierrez EG. Penetration of interleukin-6 across the murine blood-brain barrier. Neurosci Lett 1994;179:53&#x2013;56.</Citation><ArticleIdList><ArticleId IdType="pubmed">7845624</ArticleId></ArticleIdList></Reference><Reference><Citation>Rossi D, Volanti P, Brambilla L, et al. . CSF neurofilament proteins as diagnostic and prognostic biomarkers for amyotrophic lateral sclerosis. J Neurol 2018;265:510&#x2013;521.</Citation><ArticleIdList><ArticleId IdType="pubmed">29322259</ArticleId></ArticleIdList></Reference><Reference><Citation>Gille B, De Schaepdryver M, Dedeene L, et al. . Inflammatory markers in cerebrospinal fluid: independent prognostic biomarkers in amytrophic lateral sclerosis? J Neurol Neurosurg Psychiatry 2019;Epub 2019 June 7.</Citation><ArticleIdList><ArticleId IdType="pubmed">31175169</ArticleId></ArticleIdList></Reference><Reference><Citation>Weydt P, Yuen EC, Ransom BR, M&#xf6;ller T. Increased cytotoxic potential of microglia from ALS-transgenic mice. Glia 2004;48:179&#x2013;182.</Citation><ArticleIdList><ArticleId IdType="pubmed">15378658</ArticleId></ArticleIdList></Reference><Reference><Citation>Gifondorwa DJ, Jimenz-Moreno R, Hayes CD, et al. . Administration of recombinant heat shock protein 70 delays pripheral muscle denervation in the SOD1(G93A) mouse model of amyotrophic lateral sclerosis. Neurol Res Int 2012;2012:170426.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC3415202</ArticleId><ArticleId IdType="pubmed">22900172</ArticleId></ArticleIdList></Reference><Reference><Citation>Barbeito LH, Pehar M, Cassina P, et al. . A role for astrocytes in motor neuron loss in amyotrophic lateral sclerosis. Brain Res Brain Res Rev 2004:47:263&#x2013;274.</Citation><ArticleIdList><ArticleId IdType="pubmed">15572176</ArticleId></ArticleIdList></Reference><Reference><Citation>Liddelow SA, Guttenplan KA, Clarke LE, et al. . Neurotoxic reactive astrocytes are induced by activated microglia. Nature 2017;541:481&#x2013;487.</Citation><ArticleIdList><ArticleId IdType="pmc">PMC5404890</ArticleId><ArticleId IdType="pubmed">28099414</ArticleId></ArticleIdList></Reference><Reference><Citation>Castrillo-Viguera C, Grasso DL, Simpson E, Shefner J, Cudkowicz ME. Clinical significance in the change of decline in ALSFRS-R. Amyotroph Lateral Scler 2010;11:178&#x2013;180.</Citation><ArticleIdList><ArticleId IdType="pubmed">19634063</ArticleId></ArticleIdList></Reference></ReferenceList></PubmedData></PubmedArticle></PubmedArticleSet>